AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Free Cash Flow · Q4 FY2024 · quarter ended Dec 2024
Free cash flow of -€12.8M in Q4 FY2024
Q4 FY2024 free cash flow was -€12.8M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
Currency unavailable · from the cash flow
No Free Cash Flow data reported for this period type.
Free Cash Flow vs competitors
How AGMB compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $351.8M USD | +1.4% | +49.8% | 4755.3% |
| LTM Mar 2026 | $52.27M USD | +8.5% | -11.6% | 624.8% | |
| LTM Mar 2026 | $18.93M USD | +2.5% | +36.2% | — | |
| LTM Mar 2026 | $4.41M USD | +104.0% | — | 1.9% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | +5.5% | +36.2% | 624.8% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.